A synergy between b-amyloid (Ab) and tau appears to occur in Alzheimer disease (AD), but the mechanisms of interaction, and potential locations, are little understood. This study investigates the possibility of such interactions within the cortical synaptic compartments of APP/ PS1 mice. We used label-free quantitative mass spectrometry to study the phosphoproteome of synaptosomes, covering 2400 phosphopeptides and providing an unbiased survey of phosphorylation changes associated with amyloid pathology. Hyperphosphorylation was detected on 36 synaptic proteins, many of which are associated with the cytoskeleton. Importantly, tau is one of the most hyperphosphorylated proteins at the synapse, upregulated at both proline-directed kinase (PDK) sites (S199/S202, S396/S404) and nonPDK sites (S400). These PDK sites correspond to well-known pathological tau epitopes in AD patients, recognized by AT8 and PHF-1 antibodies, respectively. Hyperphosphorylation at S199/S202, a rarely examined combination, was further validated in patient-derived human synaptosomes by immunoblotting. Global surveys of upregulated phosphosites revealed 2 potential kinase motifs, which resemble those of cyclin-dependent kinase 5 (CDK5, a PDK) and casein kinase II (CK2, a nonPDK). Our data demonstrate that, within synaptic compartments, amyloid pathology is associated with tau hyperphosphorylation at disease-relevant epitopes. This provides a plausible mechanism by which Ab promotes the spreading of tauopathy.
INTRODUCTION
Alzheimer disease (AD) is a neurodegenerative disorder uniquely defined by the aggregation of 2 polypeptides, b-amyloid (Ab) and tau, while many others exhibit only one major misfolded species (1, 2) . The interaction between Ab and tau is a critical but unresolved issue in understanding AD pathogenesis (3, 4) . AD is generally considered to be an amyloidinduced tauopathy, because familial AD cases are caused by mutations that affect Ab production (5), whereas tau mutations cause frontotemporal lobar dementia (6) . In the neocortical region (except the entorhinal cortex), the aggregation of Ab precedes that of tau (7) (8) (9) (10) , but the latter is better correlated with neuronal death and cognitive decline (10, 11) . However, the best pathological correlate with clinical dementia is neither protein aggregation nor neuronal loss, but the loss of synapses (12, 13) , implying that AD may fundamentally be a synaptic disorder (4, 14, 15) .
Ab is secreted in response to synaptic activity (16) , and its primary toxic effects in vivo appear to be mediated by Ab oligomers against synaptic terminals (17, 18) . Tau is also secreted in response to synaptic activity (19, 20) , and pathological forms of tau gradually spread across synaptically connected brain regions during the natural progression of AD (21, 22) . The transmission of abnormal tau along synaptic networks has been demonstrated in several animal models (23) (24) (25) (26) , and its propagation into cortical regions is accelerated by misfolded Ab (27) . We have shown that hyperphosphorylated tau (p-tau) oligomers frequently accumulate at synapses in AD subjects (28, 29) . Moreover, in the rare cases of cognitively normal people with severe plaque and tangle pathologies, their synapses are relatively free of tau oligomers (30) . On the other hand, elderly dogs with cognitive impairment do not develop neurofibrillary tangles, but still exhibit p-tau accumulation at synapses (31) . These observations suggest that synaptic tau pathology may be better correlated with dementia than the accumulation of neurofibrillary tangles in the somatodendritic compartment. It is still unclear what causes synaptic tau pathology in AD, and we hypothesized that misfolded Ab may be a trigger.
Notably, p-tau does not just form aggregates in AD, but also in a dozen other neurodegenerative disorders (32) . One of the great obstacles in understanding the onset of different tauopathies stems from its complex phosphorylation patterns, reported at more over 40 residues (33, 34) . A recent study found over 30 phosphosites being strongly elevated in AD over controls by quantitative mass spectrometry (35) , but their examination of end-stage AD tissues did not provide insights into early phosphorylation events during pathogenesis. It remains unknown if amyloid pathology can initiate tau hyperphosphorylation in brain synapses of humans or rodents.
To gain mechanistic insights into the initial phase of tau abnormality, we chose the APPswe/PSEN1dE9 (APP/PS1) mouse model, which develops severe amyloid pathology but only subtle tauopathy. These mice overexpress mutant amyloid precursor protein (APP) and presenilin 1 (PSEN1) to promote Ab production (36) , developing heavy plaque burdens with some dystrophic neurites, but no neurofibrillary tangles (37) . With this model, we could study endogenous, nonoverexpressed tau and its changes due to amyloidosis. We aimed to address these unanswered questions about amyloid and tau pathologies at synaptic sites: 1) Does amyloidosis trigger tau hyperphosphorylation? 2) What other proteins are being hyperphosphorylated? 3) What are the common features of hyperphosphorylated proteins at the synapse? The questions were answered by combining synaptosome isolation with quantitative mass spectrometry to provide an unbiased survey of all possible phosphosites, leading to new insights into Abtau synergies.
MATERIALS AND METHODS

Reagents
Triethylammonium bicarbonate (TEABC), iron (III) chloride, formic acid, acetic acid, and HPLC-grade acetonitrile were purchased from Sigma-Aldrich (St. Louis, MO). Tris(2-carboxyethyl)phosphine (TCEP), dithiothreitol (DTT), and BCA protein assay kit were obtained from Pierce (Rockford, IL). Modified sequencing-grade trypsin was purchased from Promega (Madison, WI). Ammonium persulfate (APS) and N, N, N 0 , N 0 -tetramethylenediamine (TEMED) were purchased from Amersham (Piscataway, NJ). Ni-NTA silica resin was purchased from Qiagen (Hilden, Germany). SDB-XC Empore disks were obtained from 3M (St. Paul, MN). DA9 (total tau) and PHF-1 (pS396/pS404 tau) antibodies were gifts of Peter Davies (Albert Einstein College of Medicine). Rabbit antitau (A20024) was purchased from Dako (Glostrup, Denmark); Rabbit antipS199/pS202 tau (44-768G) was purchased from Invitrogen (Carlsbad, CA); Mouse antipT181 tau (MN1050); and rabbit antipS416 (PA1-4739) tau were purchased from Thermo (Waltham, MA). Goat antirabbit IgG-IRDye 800 CW was purchased from Li-Cor (Lincoln, NE). Donkey antimouse IgG-AlexFluor 680 was purchased from Jackson Immunoresearch (West Grove, PA).
Experimental Animals
APPswe/PS1dE9 mice (APP/PS1) were obtained from Jackson Laboratory (Bar Harbor, MA) stock line B6.Cg-Tg (APPswe, PSEN1dE9) 85Dbo/Mmjax. According to Jackson Laboratory, this line has cortical plaques by 6 months and dystrophic neurites by 9 months. Brain tissues were extracted from 11-to 12-month-old APP/PS1 mice and their wild-type littermate controls, at an age with abundant cortical and hippocampal plaques. All animal experiments conformed to United States National Institutes of Health guidelines and were approved by the Institutional Animal Care and Use Committees of Massachusetts General Hospital.
Human Subjects
Frontal cortex tissues from human subjects with a diagnosis of AD or no cognitive deficits were obtained through the Massachusetts Alzheimer's Disease Research Center and Massachusetts General Hospital Neuropathology Department. All donor tissue was obtained in accord with local and national IRB regulations. Characteristics of control and AD subjects are listed in Supplementary Data Table S1 .
Synaptosome Preparation
After mice were killed the brain was quickly removed from the skull without perfusion, and the cerebrum was excised and transferred to a microcentrifuge tube on ice, followed by rapid freezing in liquid nitrogen, and stored at À80 C. Frozen mouse cortical tissue was thawed on ice, then gently ground in a Potter-Elvehjem homogenizer with 1.5 mL ice-cold sucrose buffer (20 mM HEPES pH 7.5, 0.3 M sucrose), with 1X protease inhibitor cocktail with EDTA (Roche, Penzberg, Germany), 0.5Â phosphatase inhibitor cocktail 2 and 3 from Sigma, and 2 mM DTT. A few short strokes were applied to disrupt the tissue, followed by 6 upand-down strokes to homogenize, at 170 rpm. The brain homogenate was passed through 2 layers of 20-lm nylon filters (Millipore, Billerica, MA) to remove tissue debris. The filtrate was centrifuged at 500g for 4 minutes twice to sediment nuclei and debris, and the supernatant S1 was collected. Supernatant S1 was centrifuged at 12 000g for 15 minutes, and the resulting supernatant S2 was collected as crude cytosol. The pellet P2 was resuspended in 1.3 mL sucrose buffer and centrifuged at 12 000g for 15 minutes, resulting in the P2 0 pellet containing synaptosomes. For Western blotting analysis, the synaptosome pellet was resuspended in 20 mM Tris pH 7.5, 1.5% SDS, 2 mM DTT and boiled for 5 minutes, then centrifuged at 15 000g for 15 minutes to yield the synaptosome extract. Supernatant S2 was centrifuged at 100 000g for 30 minutes to remove all organelles, followed by adding SDS to 1% final concentration and boiling for 5 minutes to yield the cytosolic extract. Human synaptosomal and cytosolic extracts were prepared as described previously (28) based on similar procedures.
Gel-assisted Digestion
Protein samples (400 lg) from mouse synaptosomes were subjected to gel-assisted digestion (38, 39) . The synaptosome pellet was resuspended in 6 M urea, 5 mM EDTA, and 2% SDS in 0.1 M TEABC and sonicated by a Bioruptor (Diagenode, Liege, Belgium) at 4 C for 10 minutes. Protein concentration was measured by BCA assay to normalize protein amounts from different samples. Before protein digestion, a standard phosphoprotein, 0.125 mg of b-casein, was spiked into each sample to control the variation from sample preparation and instrument. Proteins were reduced by 5 mM TCEP and alkylated by 10 mM iodoacetamide at room temperature for 30 minutes. The protein sample was fixed into a gel directly in the microcentrifuge tube with acrylamide/bisacrylamide solution (40%, v/v, 29:1), 10% (w/v) APS, TEMED with a 14:5:0.7:0.3 ratio (v/v). The gel was cut into small pieces and washed several times with 25 mM TEABC containing 50% acetonitrile. The gel samples were further dehydrated with 100% acetonitrile and then completely dried by vacuum centrifugation. Trypsin was then added into the gel for proteolytic digestion (protein: trypsin ¼ 10:1, w/w) in 25 mM TEABC with incubation overnight at 37 C. Digested peptides were extracted 3 times with 5% formic acid in 50% acetonitrile for 30 minutes, dried completely by vacuum centrifugation at room temperature.
Immobilized Metal Ion Affinity Chromatography (IMAC) Procedure
Phosphopeptide enrichment was performed using IMAC protocol previously reported (40, 41) . The in-houseconstructed IMAC tip was capped at one end with a 20-lm polypropylene frits disk (Agilent, Wilmington, DE) enclosed in a tip-end fitting. The tip was packed with 20 mg of Ni-NTA silica resin. First, Ni 2þ ions were removed with 50 mM EDTA in 1 M NaCl. The tip was then activated with 100 mM FeCl 3 and equilibrated with loading buffer (6% acetic acid [v/v] at pH 3.0) prior to sample loading. Tryptic peptides were reconstituted in loading buffer and loaded onto the IMAC tip. After successive washes with 6% acetic acid, 25% acetonitrile, and 6% acetic acid, the bound peptides were eluted with 200 mM NH 4 H 2 PO 4 . The eluted peptides were desalted using reverse phase-StageTips (SDB-XC, Thermo, Waltham, MA).
LC-MS/MS Analysis
Tryptic peptides were reconstituted in buffer A (0.1% formic acid in water) and analyzed on TripleTOF 5600 system (AB SCIEX, Framingham, MA) equipped with a nanoACQ-UITY UPLC (Waters Corporation, Milford, MA). The samples were loaded and analytically separated on a 15-cm column with 100-lm inner diameter, packed in-house with 3-lm C18 particles (Dr. Maisch, Ammerbuch, Germany). The LC mobile phase system consisted of water with 0.1% formic acid (buffer A) and acetonitrile with 0.1% formic acid (buffer B). Peptides from each sample were separated by a gradient of buffer B up to 80% in 60 minutes with a flow rate of 500 nL/min in nanoACUQITY UPLC system. MS survey scan range was m/z 300-1500 for 250 ms and the top 10 precursor ions were selected for MS/MS scans for 200 ms each.
Database Search
Raw MS/MS data from the TripleTOF 5600 system were transformed to mgf files using MS Data Converter software (AB SCIEX). The mgf files were searched using Mascot (version 2.3) against the Swisssprot_Mus musculus database with the following rules: Only tryptic peptides with up to 2 missed cleavage sites were allowed, the fragment ion mass tolerance was set at 0.1 Da, and the parent ion tolerance of 20 ppm. Phosphorylation (STY), and oxidation (M) were specified as variable modifications, and carbamidomethylation (C) as fixed modification. Peptides were considered identified if their MASCOT significance threshold met p < 0.01. All MASCOT-assigned phosphosites were verified by manual inspection of MS/MS spectra. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier PXD003374. A complete list of identified phosphopeptides can be found in the supporting electronic file (see Supplementary Data Phosphopeptide list).
Quantitative Analysis by IDEAL-Q
Quantitative analysis of phosphopeptides was performed by the SEMI label-free algorithm (42) and IDEAL-Q software (43) . The raw data files acquired from the TripleTOF 5600 system were converted into files with mzML format by MS Data Converter software and search results in MASCOT were exported in eXtensive Markup Language data (.XML) format. After data conversion, the confident peptide identification results (p < 0.01) from each LC-MS/MS run were loaded and merged to establish a global peptide information list (sequence, elution time and m/z). Alignment of elution time was then performed based on the peptide information list using linear regression in different LC-MS/MS runs followed by correction of aberrational chromatographic shifts across fragmental elution-time domains. To increase correct assignments, the detected peptide peaks were validated by the SCI rule using 3 criteria: 1) signal-to-noise (S/N) ratio >3, 2) accurate charge state, and 3) correct isotope pattern. To calculate relative peptide abundance, the tool performed reconstruction of extracted ion chromatography (XIC), and calculation of XIC area. The fold-change of a given peptide was calculated by the ratio of relative peptide abundance between different samples. Finally, the quantitation result of each phosphopeptide was manually checked.
Gel Electrophoresis
To resolve proteins, 5%-16% gradient gels were prepared using the Bio-Rad mini format electrophoresis system and acrylamide/bisacrylamide (37.5:1) from Bio-Rad (Hercules, CA). Each 1.0-mm, 10-well gradient gel was made by creating a 3-layer gradient with (from bottom to top): 2.2 mL of 16% gel solution (300 mM Tris pH 8.8, 16% acrylamide, 6% sucrose, 0.1% SDS, 0.05% APS, 0.05% TEMED), 3.0 mL of 10.5% gel solution (300 mM Tris pH 8.8, 10.5% acrylamide, 3% sucrose, 0.1% SDS, 0.05% APS, 0.05% TEMED), and 5% gel solution (300 mM Tris pH 8.8, 5% acrylamide, 0.1% SDS, 0.05% APS, 0.1% TEMED) filled to the top. Gradient boundaries were naturally mixed by adding each layer via an electrical pipette at normal speeds, followed by gentle shaking of the gel. Protein extracts were mixed with 5X sample loading buffer (250 mM Tris pH 7.5, 7.5% SDS, 150 mM DTT, 0.2% orange G, 50% glycerol) and boiled just before loading. Electrophoresis was carried out at room temperature in SDS running buffer (25 mM Tris base, 192 mM glycine, 0.1% SDS). The applied voltage was 55 V for 25 minutes for stacking, followed by 150 V for 80-90 minutes.
Western Blotting
For immunoblotting, proteins in gels were transferred to PVDF membranes using Bio-Rad mini format electrophoresis system (buffer contains 25 mM Tris base, 192 mM glycine and 20% MeOH) for 2.5 hours at 70 V in a cold bath. PVDF membranes with transferred proteins were blocked with Li-Cor blocking buffer (50% dilution in PBS, 0.1% Tween 20). Primary antibodies and fluorophore-conjugated secondary antibodies were applied in blocking reagent, followed by fluorescence detection on Li-Cor Odyssey laser scanner. Band intensities were quantified by densitometry using the gel analysis function in ImageJ software (version 1.47, National Institute of Health).
Statistical Analysis
The Student and Welch t-tests were computed using Microsoft Excel and GraphPad Prism version 5.0 (La Jolla, CA). To compare peptide intensities between transgenic and control mice, we used two-tailed t-test with equal variance (4 biological replicates in each group). The average intensity of the peptide in each animal was calculated from 3 technical replicates measured by LC-MS/MS.
Functional Analysis by ClueGO
We used Cytoscape with ClueGo plugin (44) to perform the functional analysis of all hyperphosphorylated proteins from APP/PS1 synaptosomes. Molecular function pathways (2015/11/06 build version) were used for calculation (p < 0.01). Right-sided hypergeometric testing with a Bonferroni step down p value correction factor was applied for the enrichment analysis. The GO terms are demonstrated as nodes and the connectivity between terms is calculated with kappa score (!0.4). The medium network specificity was used and each node with at least 3 genes was represented.
RESULTS
Identification of Phosphorylation Sites on Synaptic Tau
To unbiasedly survey phosphosites across the synaptic proteome, we utilized a label-free quantification approach. The overall proteomics workflow is schematically presented in Figure 1A . First of all, synaptosomes were collected by subcellular fractionation of mouse brain tissues, verified by the enrichment of synaptic marker proteins synaptophysin and PSD-95 (Supplementary Data Fig. S1 ). For the efficient digestion of synaptosome proteins, which contained many membrane proteins and dense protein assemblies (such as postsynaptic densities), we used gel-assisted trypsin digestion to enhance sequence coverage (45) . Phosphopeptides were enriched by IMAC and analyzed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). A total of 2407 unique phosphopeptides were confidently identified at <1% false detection rate in 858 proteins (see Supplementary Data File).
By immunoblotting, we observed that synaptosomes of APP/PS1 and control mice exhibit similar levels of tau protein (Fig. 1B, C) . Synaptic tau protein from both strains of mice showed identical phosphorylation sites, identified across 21 phosphopeptides associated with 12 Ser/Thr residues (Table) . The sample spectrum of a doubly phosphorylated peptide (pS199/pS202) is shown in Figure 2 . All phosphopeptides were consistently observed in every control and transgenic animal, suggesting that our LC-MS/MS analyses were stable and reproducible.
Ten out of 12 tau phosphosites on mouse tau corresponded to conserved Ser/Thr residues on human tau (T181, S198, S199, S202, S231, S235, S396, S400, S404, and S416, numbered according to 441-residue human full-length tau). The alignment of mouse tau phosphosites against human tau sequence is shown in Figure 3 . All 10 sites have been previously identified as phosphorylated residues on tau aggregates isolated from AD subjects (46) (47) (48) (49) , suggesting a strong conservation between mouse and human tau phosphorylation patterns.
Synaptic Tau Is Moderately Hyperphosphorylated in APP/PS1 Mice
Although identical tau phosphosites were found in APP/ PS1 and control synaptosomes, the extent of phosphorylation at each site may differ. We adopted a label-free quantification approach in which phosphopeptide peaks were aligned across different sample runs and chromatographic peak areas were normalized to the internal standard and quantified. Samples were normalized by digesting the same amount of synaptosomal proteins. Quantitation results of synaptic tau phosphopeptides are summarized in Table and Supplementary Data  Table S2 .
In Table, 5 tau phosphopeptides show >2-fold increase in APP/PS1 over controls, while none shows <0.5-fold change. By the Student t-test, 5 phosphopeptides are significantly upregulated in APP/PS1 mice (p < 0.05), but none is significantly downregulated. Therefore, tau appears to be moderately hyperphosphorylated in the synaptosomes of APP/ PS1 mice.
The selection criteria we chose for detecting hyperphosphorylation sites were >2-fold change and p < 0.05. Only 3 tau phosphopeptides met this stringent criterion: pS396/ pS400/pS404, pS404, and pS416. There were 2 additional phosphopeptides that reached statistical significance (p < 0.05) but just short of 2-fold change-pS199/pS202 (1.87-fold) and pS396 (1.86-fold) (Table) . The MS/MS spectra of these phosphopeptides are shown in Supplementary Data Figures S2-S6 , and these sites have been further examined by immunoblotting, as described below.
Site Validation by Phospho-Specific Tau Antibodies
Using an antibody specific to pS199/pS202 double phosphosite, it was found to be significantly hyperphosphorylated by immunoblotting in both synaptosomal and cytosolic compartments of APP/PS1 mouse brains (Figs. 4, 5) . Because pT205 was not detected in our MS dataset, we are confident that the epitope being recognized is pS199/pS202 instead of 
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Amyloid-Induced Hyperphosphorylation of Synaptic Tau pS202/pT205. Hence, S199/S202 is a confirmed hyperphosphorylation site based on MS and Western blot data. On the other hand, immunoblotting against pS416 did not show significant changes in either synaptosomal or cytosolic extract (Figs. 4, 5) . Both immunoblotting and LC-MS signals were relatively weak for S416 compared with other phosphosites. Since neither method can determine phosphorylation stoichiometry, we can only suspect that S416 may be a low stoichiometry site and therefore difficult to quantify by immunoblotting, which has inherently higher background signals than LC-MS measurements. Thus, we were unable to confirm that S416 was hyperphosphorylated through immunoblotting.
The validation of pS396/pS400/pS404 hyperphosphorylation using antibodies is challenging in several aspects. First, there is no triple-phospho-specific antibody available for this site. Secondly, this region exhibits a highly heterogeneous phosphorylation pattern in MS data, with 5 other phosphorylation configurations detected: pS396, pS400, pS404, pS396/pS400, pS396/pS404. It is very difficult to measure or predict how the binding property of a particular phospho-specific antibody is affected by such heterogeneity. As a compromise, we chose PHF-1 antibody (pS396/pS404) to probe this region, which is a popular antibody for detecting pathological tau species in neuropathological studies (50) . PHF-1 levels showed significant upregulation in the cytosolic extracts of APP/PS1 mice (Fig. 5 ), but only a slight increase without reaching statistical significance in synaptosomal extracts (Fig. 4) . The MS data for pS396/pS404 peptides in synaptosomal extracts also did not show significant increases, but mono-phosphorylation at pS396 and pS404 both showed significant increases (Table) . Judging from combined MS and immunoblotting results, we consider S396/S400/S404 as a valid hyperphosphorylation site.
Validation of pS199/pS202 in Synaptosomes of AD Subjects
We have previously shown that synaptosomes of AD subjects exhibited tau hyperphosphorylation at S202 and S396/S404 (28) . Because our data suggested that pS199/ pS202 may be highly relevant for synaptic pathology, and that this duo-phosphosite has rarely been studied in previous literature, we sought to validate its relevance at human neuronal synapses. We used the pS199/pS202-specific antibody to probe synaptosomal and cytosolic extracts prepared from brain tissues of AD subjects and nondemented controls ( Fig. 6A; Supplementary Data Fig. S7 ). In nondemented elderly, pS199/pS202 signals were detectable in both cytosol and synaptosomes. In AD subjects, pS199/pS202 levels were significantly elevated in synaptosomes (p ¼ 0.0255, Welch t-test), but only borderline significant for the cytosol (p ¼ 0.0502) (Fig. 6B) . Disease-related changes at pS199/ pS202 appears to preferentially occur at synaptic terminals in AD subjects, and our mouse data suggest that such changes may be induced by the synaptotoxicity of Ab.
Tau Is a Primary Target of Hyperphosphorylation at Synapses
In the phosphoproteomics dataset of mouse synaptosomes, a total of 2407 phosphopeptides were detected and quantified (Supplementary Data File) . The global phosphorylation pattern is very similar between control and APP/PS1 mice. Under the stringent criteria of >2-fold change and p < 0.05 (Student t-test), 43 phosphopeptides were found to be elevated in APP/PS1 mice, associated with 35 synaptosomal proteins (excluding tau) (Supplementary Data Table S3 ). In contrast, no peptide showed clearly reduced phosphorylation [A] mice, using phosphospecific (pS199/pS202, PHF-1, pS416) and phosphoindependent (total) tau antibodies. (B) p-tau levels are normalized against total tau levels and plotted for each probed site. Phosphorylation levels at each site are normalized to control mice (n ¼ 6 in each group; *p < 0.05, **p < 0.01, two-tailed Welch t-test).
(<0.5-fold, p < 0.05). Among the proteins showing increased phosphorylation, the most affected functional category is cytoskeleton-associated proteins, followed by cell-surface channels/receptors (Fig. 7A) .
Remarkably, tau exhibits more hyperphosphorylation sites than any other synaptic protein in MS data (>2-fold change, p < 0.05), suggesting that a specific biochemical pathway may link Ab toxicity to tau modification. Functional network analysis suggests that hyperphosphorylated proteins are particularly involved in calmodulin binding networks (Fig. 7B) , possibly affecting calcium signaling pathways at synapses. Other affected functional clusters included glycoprotein [A] mice, using phospho-specific (pS199/pS202, PHF-1, pS416) and phospho-independent (total) tau antibodies. (B) p-tau levels are normalized against total tau levels and plotted for each probed site. Phosphorylation levels at each site are normalized to control mice (n ¼ 6 in each group; *p < 0.05, **p < 0.01, two-tailed Welch t-test). Immunoblotting against tau in human synaptosomal extracts and cytosolic extracts using pS199/pS202 and phospho-independent (total) tau antibodies. (B) The levels of p-tau are normalized against total tau levels and plotted. p values are calculated by two-tailed Welch t-test (n ¼ 8 for controls; n ¼ 12 for AD).
binding, glutamate receptor binding, and unfolded protein binding (chaperones).
Identification of Upregulated Kinase Motifs
Combining MS and immunoblotting data, we identified 5 high-confidence hyperphosphorylation sites on synaptic tau in APP/PS1 mice. Among these, S199, S202, S396, and S400 are proline-directed kinase (PDK) sites (followed by a proline), whereas S400 is a nonPDK site. Of the PDKs known to target tau, only 3 have been reported to target these 4 prolinedirected sites-cyclin-dependent kinase 5 (CDK5), extracellular signal-regulated kinases (ERK1/2), and glycogen synthase kinase 3b (GSK3b) (33) . GSK3b has been reported to target 40 sites on tau, which include all 10 phosphorylation sites and all 5 hyperphosphorylation sites in our data. In contrast, CDK5 and ERK1/2 appear to be more site-specific, only reported to target 12 and 17 residues on tau, respectively (Supplementary Data Table S4 ).
Elevated phosphopeptides (excluding tau) in APP/PS1 synaptosomes can be classified into 3 basic categories based on sequence features-proline-directed sites (S/T þ P, 24 sites), acid-directed sites (S/T þ D/E, 7 sites), and a third category without either feature (12 sites). For each category, we built the sequence motif logo and compared them to the consensus motifs extracted from PhosphoSitePlus database (51) for known tau kinases (33) . For proline-directed sites, the motif emerging from our dataset is SPKK, which resembles the consensus motif of CDK5, but not that of ERK1/2, GSK3b, or other PDKs reported to target tau (Supplementary Data Fig.  S8 ). For acid-directed sites, the generated motif, SD(D/E)E, matches that of casein kinase II (CK2), especially CK2A2 (Supplementary Data Fig. S9 ). For the third category, the generated motif is not associated with known tau kinases (Supplementary Data Fig. S10 ).
Interaction Network of Hyperphosphorylated Proteins
By compiling a list of reported CDK5 substrates (Supplementary Data Table S5 ), we found that 10 of the 36 hyperphosphorylated synaptic proteins in APP/PS1 have been reported as CDK5 substrates, which include tau (MAPT), cadducin (ADD3), catenin d2 (CTNND2), GAP43, HNRNPA1, MAP1B, MAP2, MARCKS, PKP4, and STXBP1 (illustrated in Supplementary Data Fig. S11 ). Seven out of these 10 are cytoskeleton-associated proteins shown in Figure 7 . Our proteomics data imply that misfolded Ab may activate CDK5 to phosphorylate cytoskeleton-associated proteins at synaptic sites, including tau. However, this proposed pathway still requires further biochemical validation.
The functional network interactions of CDK5, CK2, tau, and 35 other hyperphosphorylated proteins in APP/PS1 synaptosomes are shown in Supplementary Data Figure S11 . Bioinformatics analysis further suggested 10 additional proteins that may be closely related to this network. Six of them are involved in various posttranslational modification pathways, including polyubiquitin (UBC), protein kinase C (PKC), histone deacetylase 1 (HDAC1), and proteins known to bind other phosphorylated proteins (YWHAB, YWHAE, CRK). Huntingtin (HTT) is also one of the predicted interactors, suggesting that some aspects of synaptic dysfunction may be related in Huntington disease and AD (52) . A somewhat unusual prediction is follicle-stimulating hormone (FSH), and higher FSH levels have been associated with AD (53) . The strongest prediction in this network model in terms of connectivity is the HDAC1-MDM2 pathway, the activity of which is known to promote p53 degradation (54) . HDAC1 has been reported to be repressed by CDK5 hyperactivity (55) , and p53 has been found to be elevated in AD subjects and may lead to tau hyperphosphorylation (56) . Therefore, it may be interesting to further examine changes in the HDAC1-MDM2-p53 pathway in APP/PS1 mice and AD subjects. 
DISCUSSION Pathological Patterns of Tau Hyperphosphorylation
There is growing evidence that the interaction between Ab and tau pathology is critical for AD pathogenesis (3, 4, 57, 58) , but it has been very difficult to elucidate when, where, and how they interact in the brain during the natural history of AD. Our data demonstrate that there is some type of specific interaction between Ab and tau at neuronal synapses before the formation of neurofibrillary tangles, making tau one of the major hyperphosphorylation targets within the synaptic compartment. Previous studies in cellular (59) (60) (61) and animal models (62) (63) (64) (65) (66) have shown that Ab induces tau hyperphosphorylation, detected at various proline-directed sites (T181, S199/S202/T205, T231/S235, and S396/S404) using phosphospecific antibodies. In contrast, our study utilized a quantitative phosphoproteomics approach to provide an unbiased global survey.
Recently, Morris et al (67) also applied label-free quantitative mass spectrometry to study the phosphorylation of tau isolated from a different amyloid mouse model (hAPP). They failed to find any hyperphosphorylation site reaching statistical significance (p < 0.05), although pS416 and the region around 198-210 showed appreciable upregulation. In contrast, our MS data detected significant hyperphosphorylation at S416, S199/202, as well as S396/S400/S404. The discrepancy may arise from the fact that Morris et al and our study used different subcellular fractions (postsynaptic density vs synaptosomes), different amyloid mouse models (hAPP vs APP/ PS1), and different enrichment schemes (tau immunoprecipitation vs IMAC).
We found that amyloid pathology induced subtle tau hyperphosphorylation within both synaptic and cytosolic compartments. However, the quantification of individual phosphosites remains very challenging. In immunoassays, the affinity of phospho-specific antibodies may be affected by neighboring phosphosites. The use of Phos-Tag gel retardation technique may help resolve tau into a dozen bands, but it still underestimates the true complexity of tau proteoforms (68) . In MS analysis, if a phosphorylated residue appears across multiple phosphopeptides, relative quantification at this site cannot be calculated-this was indeed observed for many tau phosphosites. Therefore, the numerous clustered phosphosites on tau represent quantitation challenges for both Western blot and MS analyses. Combining both MS and immunoblotting data, high-confidence hyperphosphorylation sites on synaptic tau appeared to be S199/S202 and S396/S400/S404. Other potential sites included T181, T231, and S416, each supported by a phosphopeptide showing >2-fold upregulation in MS data.
Importantly, hyperphosphorylation at S199/S202 and S396/S404 on mouse synaptic tau correlates with well-known markers for pathological p-tau in AD patients. From brain autopsy studies, it has been established that AT8 epitope (pS199/ pS202 or pS202/pT205) is an important marker of early tauopathy including pre-tangles (69) (70) (71) , and that PHF-1 epitope (pS396/pS404) is strongly associated with severe tauopathy characterized by higher-order tau aggregates, including paired-helical filaments (50, 72) . Both AT8 and PHF-1 epitopes are PDK sites, and the same goes for other useful tauopathy markers such as pT181 and pT231 (72, 73) . However, not all tau hyperphosphorylation sites are thought to be detrimental. It has been recently reported that tau phosphorylation by p38 at T205 is protective against the synaptotoxicity of Ab (74), and we did not detect any phosphorylation at this residue. Hence, the pattern of tau hyperphosphorylation observed in APP/PS1 synaptosomes appears to be pathology-related, which occurs before the onset of obvious degenerative events such as synaptic and neuronal loss.
The Interaction between Ab and Tau
The genetic removal of MAPT (tau) in amyloid mouse models ameliorates the damaging effects of Ab on synaptic and cognitive functions (75) (76) (77) , suggesting that Ab may be the initiator of synaptotoxicity, while tau is a downstream executer. We observed that excess Ab promoted the hyperphosphorylation of tau toward a pathological state, but it did not trigger widespread hyperphosphorylation across the synaptic proteome. Instead, only a few dozen proteins showed siteselective hyperphosphorylation, and the most affected functional category was cytoskeleton-associated proteins, which also included tau. Remarkably, tau exhibited the greatest number of hyperphosphorylated peptides among all synaptosome proteins. There appears to be a selective pathway which links Ab toxicity to tau abnormality at the synapse, which may play a critical role in AD pathogenesis. Recent studies have also shown that the presence of misfolded Ab can enhance the aggregation and seeding properties of human tau protein (78) .
Through phosphoproteomics analysis, we observed a pattern which implies the involvement of CDK5 in hyperphosphorylating synaptic proteins. CDK5 has been extensively studied as a key kinase in AD-related tauopathy (79) , and our data further supports its potential role in amyloid and tau pathology (33, 34) . CDK5 is activated in AD-affected brains (80, 81) , and the underlying mechanism has been attributed to calcium elevation caused by Ab, which activates calpain to cleave the regulatory p35 subunit of CDK5 into p25, causing prolonged CDK5 activation (79, 82 ). An increased p25/p35 ratio has also been observed in Tg2576 amyloid mouse model, accompanied by increased AT8 and PHF-1 immunoreactivity on tau (83) . Conversely, silencing of CDK5 reduces tauopathy in animal models of amyloid pathology (84) . Whether the calcium-calpain-CDK5 pathway is activated inside the synapse or within surrounding neurite regions remains unclear and warrants further investigation. It is also possible that some proteins are first hyperphosphorylated within neurites before they are transported into or captured at synaptic sites.
Phosphorylation at S404 or S396/S404 by CDK5 has been reported to exert a priming effect, causing GSK3b to phosphorylate S396 and/or S400 (85, 86) . On the other hand, phosphorylation at S416 may be promoted by CK1/2 activity (48), by CaMKIIa activation following calcium elevation (87) , or by PKA (88, 89) . The spatiotemporal sequence of tau phosphorylation events in AD patients is complex and remains unresolved, and it is likely to involve multiple kinases targeting overlapping sites, dependent on subcellular localization.
We also cannot rule out the possibility that the downregulation of phosphatases may lead to the hyperphosphorylation of synaptic proteins.
The potential hazards of p-tau accumulation at synapses are 2-fold. First, it may lead to oligomer deposition and disrupt synaptic functions such as the ubiquitin-proteasome system (28) . Second, misfolded p-tau may propagate into neighboring neurons via "prion-like" seeding mechanisms (90) (91) (92) . Recent studies in animal models suggest that misfolded human tau can transmit along synaptic networks (23) (24) (25) (26) , and that such transmission is accelerated by Ab pathology (27) . Tau species phosphorylated at T181, S199, and T231 are often found in cerebrospinal fluids of AD patients (93) , and tau phosphorylated at T181 and S396 has been reported in blood exosomes (94) . The fact that extracellular tau is phosphorylated at various PDK sites implies that PDK action at the synapse may promote tau secretion and "prion-like" transmission. The spreading pattern of tauopathy in AD, generally known as Braak staging (21, 22) , is uniquely different from other tauopathies, and this may arise in part from the interaction between Ab and tau pathology observed in this study.
In sum, our study demonstrated that amyloid pathology leads to tau pathology at synaptic sites. Through unbiased phosphoproteomics approach, we gained new insights about which tau hyperphosphorylation sites are induced first and what other proteins are simultaneously hyperphosphorylated. Further work is required to unveil the mechanistic link between Ab and tau pathologies at the synapse and in surrounding neurites, and our data imply that the Ca 2þ -calpain-CDK5 pathway may be a missing link that warrants further investigation. The phosphoproteomics approach devised in this study is directly applicable to human brain tissues. It is equally applicable to other tauopathies to investigate their similarities and discrepancies. It will be important to investigate the synaptic pathology of AD patients in different brain regions at different disease stages if we seek to understand the molecular events that underlie the long-range transmission of tauopathy.
